News Releases

Date Title and Summary
Feb 15, 2024 Artivion Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis and 15% on a non-GAAP constant currency basis Achieved revenue of $354.0 million for the full year of
Feb 01, 2024 Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results
ATLANTA , Feb. 1, 2024 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes.
Jan 29, 2024 Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion 72% Reduction in All-Cause Mortality and 52% Reduction in Primary
Jan 18, 2024 Artivion Obtains $350 Million in Senior Secured Credit Facilities
Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities  and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc.   (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today